Related Experiment Video

Updated: May 15, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

57.4K

Recent advances in the discovery of copper(II) complexes as potential anticancer drugs

Bartłomiej Rogalewicz1, Agnieszka Czylkowska1

  • 1Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, Żeromskiego 116, 90-924, Lodz, Poland.

European Journal of Medicinal Chemistry
|May 6, 2025
PubMed

Insights

Recent research highlights novel copper (II) anticancer complexes with nitrogen ligands. These compounds show promise for overcoming chemotherapy resistance and reducing side effects in cancer treatment.

Area of Science:

  • Medicinal Chemistry
  • Inorganic Chemistry
  • Oncology

Background:

  • Cancer remains a leading cause of mortality globally, necessitating novel therapeutic strategies.
  • Current chemotherapy faces challenges including drug resistance and severe side effects.
  • Copper (II)-based compounds possess diverse biological activities and biochemical properties relevant to cancer therapy.

Purpose of the Study:

  • To review recent advancements in copper (II) anticancer complexes.
  • To identify novel copper (II) complexes with nitrogen-containing ligands active against cancer.
  • To focus on literature published between 2019 and mid-2024.

Main Methods:

  • Comprehensive literature search of scientific databases.
  • Analysis of studies reporting copper (II) complexes with nitrogen ligands.
  • Evaluation of reported anticancer activity and mechanisms.

Main Results:

  • Identification of several active copper (II) anticancer complexes.
  • Highlighting complexes with improved selectivity and potency.
  • Discussion of structure-activity relationships for these novel compounds.

Conclusions:

  • Copper (II) complexes represent a promising avenue for developing new anticancer drugs.
  • Nitrogen-containing ligands are crucial for designing effective copper (II) anticancer agents.
  • Further research is warranted to translate these findings into clinical applications.
Keywords:
Anticancer drugCancerChemotherapyCoordination compoundCopper(II) complex

More Related Videos

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

13.9K
Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides11:04

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

9.1K

Related Concept Videos

Extraction: Advanced Methods00:56

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
393
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K